SEC Form 4 · accession 0000950142-15-000893
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dov A Goldstein M.D.
Director
Period of report
Apr 23, 2015
Accepted (ET)
Apr 27, 2015 · 6:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 23, 2015 | S | 150,000 | $109.10 | D | 1,904,594 | I | By Aisling Capital II, LP |
| Common StockF1 | Apr 24, 2015 | S | 5,743 | $108.00 | D | 1,898,851 | I | By Aisling Capital II, LP |
| Common StockF1 | Apr 24, 2015 | S | 61,726 | $106.10 | D | 1,837,125 | I | By Aisling Capital II, LP |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, and Aisling Capital Partners, LLC ("Aisling Partners"), as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.